Do analysts prefer TTRX or CALT?

Turn Therapeutics presently has a consensus price target of $8.00, suggesting a potential downside of 15.43%. Given Turn Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Turn Therapeutics is more favorable than Calliditas Therapeutics AB (publ). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Turn Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50 Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media favor TTRX or CRON?

In the previous week, Cronos Group had 2 more articles in the media than Turn Therapeutics. MarketBeat recorded 4 mentions for Cronos Group and 2 mentions for Turn Therapeutics. Cronos Group's average media sentiment score of 0.46 beat Turn Therapeutics' score of 0.34 indicating that Cronos Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Turn Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cronos Group 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer EYPT or TTRX?

In the previous week, Eyepoint Pharmaceuticals had 47 more articles in the media than Turn Therapeutics. MarketBeat recorded 49 mentions for Eyepoint Pharmaceuticals and 2 mentions for Turn Therapeutics. Turn Therapeutics' average media sentiment score of 0.34 beat Eyepoint Pharmaceuticals' score of -0.09 indicating that Turn Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eyepoint Pharmaceuticals 6 Very Positive mention(s) 9 Positive mention(s) 10 Neutral mention(s) 13 Negative mention(s) 1 Very Negative mention(s) Neutral Turn Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ETON or TTRX?

In the previous week, Eton Pharmaceuticals and Eton Pharmaceuticals both had 2 articles in the media. Turn Therapeutics' average media sentiment score of 0.34 beat Eton Pharmaceuticals' score of 0.10 indicating that Turn Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eton Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Turn Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, ANRO or TTRX?

Turn Therapeutics is trading at a lower price-to-earnings ratio than Alto Neuroscience, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alto Neuroscience N/A N/A -$63.24M -$2.42 N/A Turn Therapeutics N/A N/A -$3.19M -$0.29 N/A

Is ANRO or TTRX more profitable?

Alto Neuroscience's return on equity of -46.46% beat Turn Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Alto Neuroscience N/A -46.46% -39.09% Turn Therapeutics N/A -230.84% -53.19%

Does the media prefer ANRO or TTRX?

In the previous week, Alto Neuroscience had 18 more articles in the media than Turn Therapeutics. MarketBeat recorded 20 mentions for Alto Neuroscience and 2 mentions for Turn Therapeutics. Alto Neuroscience's average media sentiment score of 0.76 beat Turn Therapeutics' score of 0.34 indicating that Alto Neuroscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alto Neuroscience 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Turn Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Turn Therapeutics (TTRX) Competitors

$9.46 -0.08 (-0.84%)

As of 08/21/2026 04:00 PM Eastern

Compare

TTRX vs. CALT, CRON, EYPT, ETON, and ANRO

Should you buy Turn Therapeutics stock or one of its competitors? Turn Therapeutics's main competitors and comparable companies include Calliditas Therapeutics AB (publ) (CALT), Cronos Group (CRON), Eyepoint Pharmaceuticals (EYPT), Eton Pharmaceuticals (ETON), and Alto Neuroscience (ANRO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Turn Therapeutics compare to Calliditas Therapeutics AB (publ)?

Turn Therapeutics (NASDAQ:TTRX) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

Turn Therapeutics has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Calliditas Therapeutics AB (publ)'s return on equity of -212.04% beat Turn Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Turn Therapeutics	N/A	-230.84%	-53.19%
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%

In the previous week, Turn Therapeutics had 2 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 2 mentions for Turn Therapeutics and 0 mentions for Calliditas Therapeutics AB (publ). Turn Therapeutics' average media sentiment score of 0.34 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Turn Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Turn Therapeutics	Neutral
Calliditas Therapeutics AB (publ)	Neutral

2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Turn Therapeutics presently has a consensus price target of $8.00, suggesting a potential downside of 15.43%. Given Turn Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Turn Therapeutics is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Turn Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Turn Therapeutics has higher earnings, but lower revenue than Calliditas Therapeutics AB (publ). Turn Therapeutics is trading at a lower price-to-earnings ratio than Calliditas Therapeutics AB (publ), indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.29	N/A
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A

Summary

Turn Therapeutics beats Calliditas Therapeutics AB (publ) on 9 of the 15 factors compared between the two stocks.

How does Turn Therapeutics compare to Cronos Group?

Turn Therapeutics (NASDAQ:TTRX) and Cronos Group (NASDAQ:CRON) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, media sentiment, profitability and analyst recommendations.

Turn Therapeutics has higher earnings, but lower revenue than Cronos Group. Turn Therapeutics is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.29	N/A
Cronos Group	$146.59M	8.37	-$9.45M	$0.20	16.55

Cronos Group has a net margin of 39.08% compared to Turn Therapeutics' net margin of 0.00%. Cronos Group's return on equity of 4.85% beat Turn Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Turn Therapeutics	N/A	-230.84%	-53.19%
Cronos Group	39.08%	4.85%	4.62%

In the previous week, Cronos Group had 2 more articles in the media than Turn Therapeutics. MarketBeat recorded 4 mentions for Cronos Group and 2 mentions for Turn Therapeutics. Cronos Group's average media sentiment score of 0.46 beat Turn Therapeutics' score of 0.34 indicating that Cronos Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Turn Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cronos Group	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Turn Therapeutics presently has a consensus price target of $8.00, suggesting a potential downside of 15.43%. Cronos Group has a consensus price target of $2.30, suggesting a potential downside of 30.51%. Given Turn Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Turn Therapeutics is more favorable than Cronos Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Turn Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Cronos Group	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.40

8.7% of Cronos Group shares are held by institutional investors. 7.8% of Cronos Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Cronos Group beats Turn Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Turn Therapeutics compare to Eyepoint Pharmaceuticals?

Eyepoint Pharmaceuticals (NASDAQ:EYPT) and Turn Therapeutics (NASDAQ:TTRX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, profitability, dividends, media sentiment and analyst recommendations.

In the previous week, Eyepoint Pharmaceuticals had 47 more articles in the media than Turn Therapeutics. MarketBeat recorded 49 mentions for Eyepoint Pharmaceuticals and 2 mentions for Turn Therapeutics. Turn Therapeutics' average media sentiment score of 0.34 beat Eyepoint Pharmaceuticals' score of -0.09 indicating that Turn Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eyepoint Pharmaceuticals	6 Very Positive mention(s)	9 Positive mention(s)	10 Neutral mention(s)	13 Negative mention(s)	1 Very Negative mention(s)	Neutral
Turn Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Turn Therapeutics has lower revenue, but higher earnings than Eyepoint Pharmaceuticals. Turn Therapeutics is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eyepoint Pharmaceuticals	$31.37M	14.62	-$231.96M	-$3.74	N/A
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.29	N/A

Eyepoint Pharmaceuticals presently has a consensus price target of $28.11, suggesting a potential upside of 428.40%. Turn Therapeutics has a consensus price target of $8.00, suggesting a potential downside of 15.43%. Given Eyepoint Pharmaceuticals' higher possible upside, analysts clearly believe Eyepoint Pharmaceuticals is more favorable than Turn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eyepoint Pharmaceuticals	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.45
Turn Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Turn Therapeutics has a net margin of 0.00% compared to Eyepoint Pharmaceuticals' net margin of -10,994.73%. Eyepoint Pharmaceuticals' return on equity of -135.81% beat Turn Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eyepoint Pharmaceuticals	-10,994.73%	-135.81%	-108.35%
Turn Therapeutics	N/A	-230.84%	-53.19%

99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. 5.1% of Eyepoint Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Eyepoint Pharmaceuticals beats Turn Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Turn Therapeutics compare to Eton Pharmaceuticals?

Eton Pharmaceuticals (NASDAQ:ETON) and Turn Therapeutics (NASDAQ:TTRX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, profitability, valuation, risk and institutional ownership.

In the previous week, Eton Pharmaceuticals and Eton Pharmaceuticals both had 2 articles in the media. Turn Therapeutics' average media sentiment score of 0.34 beat Eton Pharmaceuticals' score of 0.10 indicating that Turn Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eton Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Turn Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

27.9% of Eton Pharmaceuticals shares are owned by institutional investors. 16.5% of Eton Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Turn Therapeutics has lower revenue, but higher earnings than Eton Pharmaceuticals. Turn Therapeutics is trading at a lower price-to-earnings ratio than Eton Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eton Pharmaceuticals	$79.95M	22.69	-$4.60M	$0.38	167.03
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.29	N/A

Eton Pharmaceuticals currently has a consensus target price of $67.50, indicating a potential upside of 6.35%. Turn Therapeutics has a consensus target price of $8.00, indicating a potential downside of 15.43%. Given Eton Pharmaceuticals' higher probable upside, equities research analysts clearly believe Eton Pharmaceuticals is more favorable than Turn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eton Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
Turn Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Eton Pharmaceuticals has a net margin of 12.02% compared to Turn Therapeutics' net margin of 0.00%. Eton Pharmaceuticals' return on equity of 40.13% beat Turn Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eton Pharmaceuticals	12.02%	40.13%	12.37%
Turn Therapeutics	N/A	-230.84%	-53.19%

Summary

Eton Pharmaceuticals beats Turn Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Turn Therapeutics compare to Alto Neuroscience?

Alto Neuroscience (NYSE:ANRO) and Turn Therapeutics (NASDAQ:TTRX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, profitability, earnings and institutional ownership.

Turn Therapeutics is trading at a lower price-to-earnings ratio than Alto Neuroscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.29	N/A

In the previous week, Alto Neuroscience had 18 more articles in the media than Turn Therapeutics. MarketBeat recorded 20 mentions for Alto Neuroscience and 2 mentions for Turn Therapeutics. Alto Neuroscience's average media sentiment score of 0.76 beat Turn Therapeutics' score of 0.34 indicating that Alto Neuroscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alto Neuroscience	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Turn Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alto Neuroscience's return on equity of -46.46% beat Turn Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alto Neuroscience	N/A	-46.46%	-39.09%
Turn Therapeutics	N/A	-230.84%	-53.19%

Alto Neuroscience presently has a consensus price target of $37.25, indicating a potential upside of 8.41%. Turn Therapeutics has a consensus price target of $8.00, indicating a potential downside of 15.43%. Given Alto Neuroscience's stronger consensus rating and higher possible upside, research analysts clearly believe Alto Neuroscience is more favorable than Turn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alto Neuroscience	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Turn Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Alto Neuroscience beats Turn Therapeutics on 8 of the 11 factors compared between the two stocks.

Get Turn Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TTRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TTRX vs. The Competition

Export

Metric	Turn Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$281.79M	$12.54B	$7.37B	$12.85B
Dividend Yield	N/A	2.61%	2.53%	11.08%
P/E Ratio	-32.62	789.80	272.60	24.24
Price / Sales	N/A	764.50	618.96	99.81
Price / Cash	N/A	96.77	78.62	53.99
Price / Book	473.00	11.89	13.05	6.20
Net Income	-$3.19M	$2.81B	$3.47B	$348.59M
7 Day Performance	-1.15%	1.77%	2.09%	0.08%
1 Month Performance	-0.21%	3.85%	6.64%	3.88%
1 Year Performance	N/A	6.56%	25.02%	16.98%

Turn Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TTRX Turn Therapeutics	1.4336 of 5 stars	$9.46 -0.8%	$8.00 -15.4%	N/A	$281.79M	N/A	N/A	2	Analyst Downgrade
CALT Calliditas Therapeutics AB (publ)	N/A	$40.00 flat	N/A	N/A	$1.19B	$1.60B	N/A	180
CRON Cronos Group	1.5452 of 5 stars	$3.16 -0.3%	$2.30 -27.2%	+27.3%	$1.18B	$146.59M	15.80	450
EYPT Eyepoint Pharmaceuticals	2.3467 of 5 stars	$13.48 -0.4%	$44.38 +229.2%	-55.0%	$1.17B	$31.37M	N/A	120	News Coverage Analyst Forecast Options Volume
ETON Eton Pharmaceuticals	2.7629 of 5 stars	$40.80 -1.9%	$54.50 +33.6%	+266.9%	$1.14B	$79.95M	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TTRX) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Turn Therapeutics (TTRX) Competitors

TTRX vs. CALT, CRON, EYPT, ETON, and ANRO

How does Turn Therapeutics compare to Calliditas Therapeutics AB (publ)?

Summary

How does Turn Therapeutics compare to Cronos Group?

Summary

How does Turn Therapeutics compare to Eyepoint Pharmaceuticals?

Summary

How does Turn Therapeutics compare to Eton Pharmaceuticals?

Summary

How does Turn Therapeutics compare to Alto Neuroscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TTRX vs. The Competition

Turn Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Turn Therapeutics (TTRX) Competitors

TTRX vs. CALT, CRON, EYPT, ETON, and ANRO

How does Turn Therapeutics compare to Calliditas Therapeutics AB (publ)?

Is TTRX or CALT more profitable?

Does the media prefer TTRX or CALT?

Do insiders and institutionals hold more shares of TTRX or CALT?

Do analysts prefer TTRX or CALT?

Which has better earnings and valuation, TTRX or CALT?

Summary

How does Turn Therapeutics compare to Cronos Group?

Which has better earnings and valuation, TTRX or CRON?

Is TTRX or CRON more profitable?

Does the media favor TTRX or CRON?

Do analysts rate TTRX or CRON?

Do institutionals & insiders believe in TTRX or CRON?

Summary

How does Turn Therapeutics compare to Eyepoint Pharmaceuticals?

Does the media prefer EYPT or TTRX?

Which has preferable earnings & valuation, EYPT or TTRX?

Do analysts rate EYPT or TTRX?

Is EYPT or TTRX more profitable?

Do insiders and institutionals believe in EYPT or TTRX?

Summary

How does Turn Therapeutics compare to Eton Pharmaceuticals?

Does the media prefer ETON or TTRX?

Do insiders and institutionals have more ownership in ETON or TTRX?

Which has better valuation and earnings, ETON or TTRX?

Do analysts prefer ETON or TTRX?

Is ETON or TTRX more profitable?

Summary

How does Turn Therapeutics compare to Alto Neuroscience?

Which has stronger earnings & valuation, ANRO or TTRX?

Does the media prefer ANRO or TTRX?

Is ANRO or TTRX more profitable?

Do analysts recommend ANRO or TTRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TTRX vs. The Competition

Turn Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools